Overview

Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca